Xavier Vidal
Impact in
- Hepatology top 1%
- Hepatitis C virus research
- Geriatrics and Gerontology top 1%
- Pharmaceutical Practices and Patient Outcomes
Papers in
-
- Pharmaceutical Practices and Patient Outcomes 10
- Co-authors
- Joan‐Ramon Laporte (20 shared papers)Luisa Ibáñez (26 shared papers)Elena Ballarín (16 shared papers)Lourdes Vendrell (8 shared papers)Dolors Capellà (9 shared papers)Xavier Castells (5 shared papers)Miguel Casas (5 shared papers)Vı́ctor Moreno (1 shared paper)
In The Last Decade
Xavier Vidal
117 papers receiving 4.8k citations
Xavier Vidal's Hit Papers
Peers
Comparison fields: 5 of 155
- Hepatology 561
- Geriatrics and Gerontology 235
- Toxicology 213
- Pharmacology 605
- Pharmacology 286
Countries citing papers authored by Xavier Vidal
This map shows the geographic impact of Xavier Vidal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xavier Vidal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xavier Vidal more than expected).
Fields of papers citing papers by Xavier Vidal
This network shows the impact of papers produced by Xavier Vidal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xavier Vidal. The network helps show where Xavier Vidal may publish in the future.
Co-authors
The 25 scholars most cited alongside Xavier Vidal, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 122 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease Hit paper breakdown → | 2014 | 435 |
| 2 | 1990 | 300 | |
| 3 | 1991 | 253 | |
| 4 | 1991 | 232 | |
| 5 | Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome Hit paper breakdown → | 2019 | 218 |
| 6 | 2004 | 203 | |
| 7 | 2005 | 146 | |
| 8 | 2011 | 138 | |
| 9 | 2008 | 129 | |
| 10 | 2004 | 127 | |
| 11 | 2010 | 107 | |
| 12 | 2005 | 102 | |
| 13 | 2010 | 96 | |
| 14 | 2002 | 91 | |
| 15 | 2008 | 81 | |
| 16 | 2016 | 78 | |
| 17 | 2016 | 77 | |
| 18 | 2015 | 74 | |
| 19 | 2007 | 72 | |
| 20 | 2009 | 71 |
About Xavier Vidal
Xavier Vidal is a scholar working on Cardiology and Cardiovascular Medicine, Geriatrics and Gerontology, Surgery, Pharmacology and Pharmacology, having authored 122 papers that have together received 4.9k indexed citations. Recurring topics across this work include Pharmaceutical Practices and Patient Outcomes (10 papers), Drug-Induced Hepatotoxicity and Protection (7 papers), COVID-19 Clinical Research Studies (6 papers), Blood disorders and treatments (5 papers), Hip and Femur Fractures (5 papers), Inflammatory mediators and NSAID effects (5 papers), Drug-Induced Adverse Reactions (4 papers) and Pharmaceutical studies and practices (4 papers). The work is most often cited by research in Hepatology (561 citations), Geriatrics and Gerontology (235 citations), Toxicology (213 citations), Pharmacology (605 citations) and Pharmacology (286 citations). Xavier Vidal has collaborated with scholars based in Spain, Ireland and Italy. Frequent co-authors include Joan‐Ramon Laporte, Luisa Ibáñez, Elena Ballarín, Lourdes Vendrell, Dolors Capellà, Xavier Castells, Miguel Casas, Vı́ctor Moreno, Xavier Carné and E. Pérez. Their work appears in journals such as European Journal of Clinical Pharmacology, Drug Safety, British Journal of Clinical Pharmacology, Frontiers in Pharmacology and Alimentary Pharmacology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.